316 related articles for article (PubMed ID: 28055978)
1. Research progress of neuroblastoma related gene variations.
Cao Y; Jin Y; Yu J; Wang J; Yan J; Zhao Q
Oncotarget; 2017 Mar; 8(11):18444-18455. PubMed ID: 28055978
[TBL] [Abstract][Full Text] [Related]
2. Exome and deep sequencing of clinically aggressive neuroblastoma reveal somatic mutations that affect key pathways involved in cancer progression.
Lasorsa VA; Formicola D; Pignataro P; Cimmino F; Calabrese FM; Mora J; Esposito MR; Pantile M; Zanon C; De Mariano M; Longo L; Hogarty MD; de Torres C; Tonini GP; Iolascon A; Capasso M
Oncotarget; 2016 Apr; 7(16):21840-52. PubMed ID: 27009842
[TBL] [Abstract][Full Text] [Related]
3. BLM germline and somatic PKMYT1 and AHCY mutations: Genetic variations beyond MYCN and prognosis in neuroblastoma.
Novak EM; Halley NS; Gimenez TM; Rangel-Santos A; Azambuja AM; Brumatti M; Pereira PL; Vince CS; Giorgi RR; Bendit I; Cristofani LM; Odone-Filho V
Med Hypotheses; 2016 Dec; 97():22-25. PubMed ID: 27876123
[TBL] [Abstract][Full Text] [Related]
4. Genetic Alterations Detected by Targeted Next-generation Sequencing and Their Clinical Implications in Neuroblastoma.
Koh KN; Lee JY; Lim J; Shin J; Kang SH; Suh JK; Kim H; Im HJ; Namgoong JM; Kim DY; Jang SJ; Chun SM
Anticancer Res; 2020 Dec; 40(12):7057-7065. PubMed ID: 33288603
[TBL] [Abstract][Full Text] [Related]
5. The biologic basis for neuroblastoma heterogeneity and risk stratification.
Maris JM
Curr Opin Pediatr; 2005 Feb; 17(1):7-13. PubMed ID: 15659956
[TBL] [Abstract][Full Text] [Related]
6. Recent biologic and genetic advances in neuroblastoma: Implications for diagnostic, risk stratification, and treatment strategies.
Newman EA; Nuchtern JG
Semin Pediatr Surg; 2016 Oct; 25(5):257-264. PubMed ID: 27955728
[TBL] [Abstract][Full Text] [Related]
7. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma.
Janoueix-Lerosey I; Lequin D; Brugières L; Ribeiro A; de Pontual L; Combaret V; Raynal V; Puisieux A; Schleiermacher G; Pierron G; Valteau-Couanet D; Frebourg T; Michon J; Lyonnet S; Amiel J; Delattre O
Nature; 2008 Oct; 455(7215):967-70. PubMed ID: 18923523
[TBL] [Abstract][Full Text] [Related]
8. Advances in the understanding of constitutional and somatic genomic alterations in neuroblastoma.
Deyell RJ; Attiyeh EF
Cancer Genet; 2011 Mar; 204(3):113-21. PubMed ID: 21504710
[TBL] [Abstract][Full Text] [Related]
9. Recent insights into the biology of neuroblastoma.
Schleiermacher G; Janoueix-Lerosey I; Delattre O
Int J Cancer; 2014 Nov; 135(10):2249-61. PubMed ID: 25124476
[TBL] [Abstract][Full Text] [Related]
10. Investigational drugs in phase II clinical trials for the treatment of neuroblastoma.
Amoroso L; Haupt R; Garaventa A; Ponzoni M
Expert Opin Investig Drugs; 2017 Nov; 26(11):1281-1293. PubMed ID: 28906153
[TBL] [Abstract][Full Text] [Related]
11. Molecular targeting therapies for neuroblastoma: Progress and challenges.
Zafar A; Wang W; Liu G; Wang X; Xian W; McKeon F; Foster J; Zhou J; Zhang R
Med Res Rev; 2021 Mar; 41(2):961-1021. PubMed ID: 33155698
[TBL] [Abstract][Full Text] [Related]
12. Integrative Genome-Scale Analysis Identifies Epigenetic Mechanisms of Transcriptional Deregulation in Unfavorable Neuroblastomas.
Henrich KO; Bender S; Saadati M; Dreidax D; Gartlgruber M; Shao C; Herrmann C; Wiesenfarth M; Parzonka M; Wehrmann L; Fischer M; Duffy DJ; Bell E; Torkov A; Schmezer P; Plass C; Höfer T; Benner A; Pfister SM; Westermann F
Cancer Res; 2016 Sep; 76(18):5523-37. PubMed ID: 27635046
[TBL] [Abstract][Full Text] [Related]
13. Genetic discoveries and treatment advances in neuroblastoma.
Bagatell R; Cohn SL
Curr Opin Pediatr; 2016 Feb; 28(1):19-25. PubMed ID: 26576010
[TBL] [Abstract][Full Text] [Related]
14. Genome and transcriptome analysis of neuroblastoma advanced diagnosis from innovative therapies.
Coco S; Tonini GP; Stigliani S; Scaruffi P
Curr Pharm Des; 2009; 15(4):448-55. PubMed ID: 19199972
[TBL] [Abstract][Full Text] [Related]
15. Global genomic and RNA profiles for novel risk stratification of neuroblastoma.
Ohira M; Nakagawara A
Cancer Sci; 2010 Nov; 101(11):2295-301. PubMed ID: 20731666
[TBL] [Abstract][Full Text] [Related]
16. Next generation sequencing of microRNAs from isogenic neuroblastoma cell lines isolated before and after treatment.
Roth SA; Knutsen E; Fiskaa T; Utnes P; Bhavsar S; Hald ØH; Løkke C; Mestdagh P; Johansen SD; Flægstad T; Einvik C
Cancer Lett; 2016 Mar; 372(1):128-36. PubMed ID: 26708804
[TBL] [Abstract][Full Text] [Related]
17. Enrichment of Targetable Mutations in the Relapsed Neuroblastoma Genome.
Padovan-Merhar OM; Raman P; Ostrovnaya I; Kalletla K; Rubnitz KR; Sanford EM; Ali SM; Miller VA; Mossé YP; Granger MP; Weiss B; Maris JM; Modak S
PLoS Genet; 2016 Dec; 12(12):e1006501. PubMed ID: 27997549
[TBL] [Abstract][Full Text] [Related]
18. Progress in treatment and risk stratification of neuroblastoma: impact on future clinical and basic research.
Øra I; Eggert A
Semin Cancer Biol; 2011 Oct; 21(4):217-28. PubMed ID: 21798350
[TBL] [Abstract][Full Text] [Related]
19. Zebrafish as a model to study neuroblastoma development.
Casey MJ; Stewart RA
Cell Tissue Res; 2018 May; 372(2):223-232. PubMed ID: 29027617
[TBL] [Abstract][Full Text] [Related]
20. Somatic mutations in specific and connected subpathways are associated with short neuroblastoma patients' survival and indicate proteins targetable at onset of disease.
Esposito MR; Binatti A; Pantile M; Coppe A; Mazzocco K; Longo L; Capasso M; Lasorsa VA; Luksch R; Bortoluzzi S; Tonini GP
Int J Cancer; 2018 Nov; 143(10):2525-2536. PubMed ID: 29992558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
